Manufacturing Capability Leverage Jaguar Gene Therapy’s growing internal CMC and manufacturing capabilities, including a planned large-scale facility in North Carolina and PPQ collaborations, to position as a reliable CDMO partner for gene therapy programs and late-stage manufacturing support.

Strategic Partnerships Target potential collaborations with companies seeking gene therapy development or manufacturing support, drawing on Jaguar’s recent partnerships with Andelyn Biosciences and investor backing from Samsung Ventures, which signal strong credibility and funding readiness.

Pipeline Synergies Explore co-development or in-licensing opportunities around JAG301 for Type 1 diabetes and SHANK3-related neurodevelopmental disorders, and assess alignment with unmet needs in PMS and ASD spaces to accelerate joint value propositions.

Clinical and Regulatory Expertise Highlight Jaguar’s experienced team in CMC, regulatory, and clinical operations as a differentiator for potential sponsors seeking efficient pathways, risk mitigation, and faster time to clinic for gene therapy programs.

Access to Patient Communities Capitalize on established relationships with patient foundations and advocacy groups (e.g., galactosemia community, PMS/ASD stakeholders) to co-create patient-centric development plans, enhance trial enrollment strategies, and strengthen market access discussions.